<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">gastro-j</journal-id><journal-title-group><journal-title xml:lang="ru">Российский журнал гастроэнтерологии, гепатологии, колопроктологии</journal-title><trans-title-group xml:lang="en"><trans-title>Russian Journal of Gastroenterology, Hepatology, Coloproctology</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1382-4376</issn><issn pub-type="epub">2658-6673</issn><publisher><publisher-name>«Gastro» LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.22416/1382-4376-2024-1215-3218</article-id><article-id custom-type="elpub" pub-id-type="custom">gastro-j-1381</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL ARTICLES</subject></subj-group></article-categories><title-group><article-title>Электрические и вязкоупругие параметры эритроцитов в составе диагностических моделей для дифференцирования жировой болезни печени смешанного генеза от неалкогольной и алкогольной жировой болезни печени</article-title><trans-title-group xml:lang="en"><trans-title>Electrical and Viscoelastic Parameters of Erythrocytes as a Part of Diagnostic Models for Differentiating Fatty Liver Disease of Mixed Genesis from Non-Alcoholic and Alcohol-Related Fatty Liver Disease</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-0077-3823</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Кручинина</surname><given-names>М. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Kruchinina</surname><given-names>M. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Кручинина Маргарита Витальевна — доктор медицинских наук, доцент; ведущий научный сотрудник, заведующая лабораторией гастроэнтерологии; профессор кафедры пропедевтики внутренних болезней</p><p>630089, г. Новосибирск, ул. Б. Богаткова, 175/1</p></bio><bio xml:lang="en"><p>Margarita V. Kruchinina* — Dr. Sci. (Med.), Docent;</p><p>Leading Researcher, Head of the Gastroenterology Laboratory; Professor of the Department of Propaedeutics of Internal Diseases</p><p>630089, Novosibirsk, B. Bogatkova str., 175/1</p></bio><email xlink:type="simple">kruchmargo@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5156-2842</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Осипенко</surname><given-names>М. Ф.</given-names></name><name name-style="western" xml:lang="en"><surname>Osipenko</surname><given-names>M. F.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Осипенко Марина Федоровна — доктор медицинских наук, профессор, заведующая кафедрой пропедевтики внутренних болезней</p><p>630091, г. Новосибирск, Красный просп., 52</p></bio><bio xml:lang="en"><p>Marina F. Osipenko — Dr. Sci. (Med.), Professor, Head of the Department of Propaedeutics of Internal Diseases</p><p> </p></bio><email xlink:type="simple">ngma@bk.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0005-8305-4091</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Паруликова</surname><given-names>М. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Parulikova</surname><given-names>M. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Паруликова Марина Владимировна — врач-гастроэнтеролог, старший преподаватель Отдела образования</p><p>630089, г. Новосибирск, ул. Б. Богаткова, 175/1</p></bio><bio xml:lang="en"><p>Marina V. Parulikova — Gastroenterologist, Senior Lecturer at the Department of Education</p><p>630089, Novosibirsk, B. Bogatkova str., 175/1</p></bio><xref ref-type="aff" rid="aff-3"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-9254-4192</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Громов</surname><given-names>А. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Gromov</surname><given-names>A. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Громов Андрей Александрович — кандидат медицинских наук, старший научный сотрудник лаборатории клинических биохимических и гормональных исследований терапевтических заболеваний, руководитель Центра профилактики тромбозов</p><p>630089, г. Новосибирск, ул. Б. Богаткова, 175/1</p></bio><bio xml:lang="en"><p>Andrei A. Gromov — Cand. Sci. (Med.), Senior Researcher at the Laboratory of Clinical Biochemical and Hormonal Studies of Therapeutic Diseases, Head of the Thrombosis Prevention Center</p><p>630089, Novosibirsk, B. Bogatkova str., 175/1</p></bio><email xlink:type="simple">gromov.center@rambler.ru</email><xref ref-type="aff" rid="aff-3"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>НИИ терапии и профилактической медицины — филиал ФГБНУ «Федеральный исследовательский центр Институт цитологии и генетики СО РАН»; ФГБОУ ВО «Новосибирский государственный медицинский университет» Министерства здравоохранения Российской Федерации</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Research Institute of Internal and Preventive Medicine — Branch of the Institute of Cytology and Genetics, Siberian Branch of the Russian Academy of Sciences; Novosibirsk State Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>ФГБОУ ВО «Новосибирский государственный медицинский университет» Министерства здравоохранения Российской Федерации</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Novosibirsk State Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>НИИ терапии и профилактической медицины — филиал ФГБНУ «Федеральный исследовательский центр Институт цитологии и генетики СО РАН»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Research Institute of Internal and Preventive Medicine — Branch of the Institute of Cytology and Genetics, Siberian Branch of the Russian Academy of Sciences</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2024</year></pub-date><pub-date pub-type="epub"><day>21</day><month>08</month><year>2024</year></pub-date><volume>34</volume><issue>3</issue><fpage>38</fpage><lpage>52</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Кручинина М.В., Осипенко М.Ф., Паруликова М.В., Громов А.А., 2024</copyright-statement><copyright-year>2024</copyright-year><copyright-holder xml:lang="ru">Кручинина М.В., Осипенко М.Ф., Паруликова М.В., Громов А.А.</copyright-holder><copyright-holder xml:lang="en">Kruchinina M.V., Osipenko M.F., Parulikova M.V., Gromov A.A.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.gastro-j.ru/jour/article/view/1381">https://www.gastro-j.ru/jour/article/view/1381</self-uri><abstract><sec><title>Цель исследования</title><p>Цель исследования: создание диагностических моделей, включающих электрические, вязкоупругие параметры эритроцитов, для различения жировой болезни печени смешанной этиологии (метаболическая + алкогольная) от неалкогольной и алкогольной жировой болезни печени.</p></sec><sec><title>Материалы и методы</title><p>Материалы и методы. Обследованы 46 мужчин с неалкогольной жировой болезнью печени (НАЖБП), 43 мужчины с алкогольной жировой болезнью печени (АЖБП) и 54 мужчины с жировой болезнью печени (ЖБП) смешанного генеза (метаболический + алкогольный); средний возраст обследованных составил 48,4 ± 9,6 года. Диагноз был выставлен на основании данных ультразвукового исследования печени и индекса стеатоза печени FLI со степенью фиброза не более F1 (FibroScan® 502, Echosens, Франция). Электрические, вязкоупругие параметры эритроцитов исследованы методом диэлектрофореза с помощью электрооптической системы детекции клеток.</p></sec><sec><title>Результаты</title><p>Результаты. Наиболее значимыми для дифференцирования ЖБП смешанного генеза (метаболический + алкогольный) от НАЖБП при использовании метода Volcano plot оказались поляризуемость клеток на частоте 106 Гц (p = 6,49 ×10-5), емкость клеточной мембраны эритроцитов (p = 0,00077) и относительная поляризуемость (p = 0,001), уровни которых были выше у пациентов с НАЖБП. Напротив, индекс деструкции эритроцитов на частоте 105 Гц оказался выше при смешанном генезе ЖБП (p = 0,047), а равновесная частота смещена в высокочастотный диапазон по сравнению с показателями при НАЖБП (p = 0,0005). Дискриминантный анализ дополнительно выявил значимость степени деформации эритроцитов на частоте 5 ×105 Гц в различении ЖБП смешанного генеза и НАЖБП. Диагностическая модель при дифференцировании ЖБП смешанного генеза от НАЖБП, включающая вышеописанные параметры эритроцитов, обеспечила AUC 0,829 (доверительный интервал (ДИ): 0,742–0,916), чувствительность — 80,9 %, специфичность — 83,3 %.</p><p>Установлены два показателя эритроцитов, статистически значимо отличающие жировую болезнь печени смешанного генеза от АЖБП (Volcano plot), — это индекс деструкции на частоте 5 ×105 Гц, который был выше при АЖБП (p = 0,0007), и емкость мембран клеток, величина которой преобладала при ЖБП смешанного генеза (p = 0,011). При различении ЖБП смешанного генеза от АЖБП комбинированная модель с включением трех параметров эритроцитов — индекса деструкции на частоте 5 ×105 Гц, емкости мембран эритроцитов и поляризуемости на частоте 106 Гц — показала наиболее высокие уровни диагностической точности: AUC = 0,751 (ДИ: 0,611–0,908) с чувствительностью 79,5 %, специфичностью 74,7 %.</p></sec><sec><title>Заключение</title><p>Заключение. Электрические и вязкоупругие параметры эритроцитов, изученные с помощью метода диэлектрофореза, следует рассматривать как перспективные биомаркеры для диагностики диффузной патологии печени.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Aim</title><p>Aim: creation of diagnostic models including electrical, viscoelastic parameters of erythrocytes to distinguish fatty liver disease of mixed etiology (metabolic + alcoholic) from non-alcoholic and alcoholic fatty liver disease.</p></sec><sec><title>Materials and methods</title><p>Materials and methods. We examined 46 men with non-alcoholic fatty liver disease (NAFLD), 43 men with alcoholic fatty liver disease (AFLD), as well as 54 men with fatty liver disease (FLD) of mixed genesis (metabolic + alcohol-related); average age of the patients included in the study made 48.4 ± 9.6 years. The diagnosis was established on the basis of liver ultrasound findings and FLI liver steatosis index with a fibrosis grade of F1 or less (FibroScan® 502, Echosens, France). The electrical and viscoelastic parameters of erythrocytes were investigated by the diagnostic technique of dielectrophoresis using an electrooptical cell detection system.</p></sec><sec><title>Results</title><p>Results. The most significant parameters for differentiating fatty liver disease of mixed genesis (metabolic + alcoholic) from NAFLD using the Volcano plot have turned out to be cell polarizability at a frequency of 106 Hz (p = 6.49 ×10-5), erythrocyte cell membrane capacity (p = 0.00077), relative polarizability (p = 0.001), the levels of which were higher in patients with NAFLD. On the contrary, the index of red blood cells destruction at 105 Hz was higher in FLD of the mixed genesis (p = 0.047) and the crossover frequency was shifted to the high frequency range more than in NAFLD (p = 0.0005). The discriminant analysis has additionally revealed the significance of the degree of erythrocyte deformation at 5 ×105 Hz in distinguishing between mixed-genesis FLD and NAFLD. In differentiating FLD of mixed genesis from NAFLD, a diagnostic model incorporating the above red blood cells parameters has provided an AUC of 0.829 (confidential interval: 0.742–0.916), sensitivity of 80.9 %, and specificity of 83.3 %. Two indicators of red blood cells have been established that statistically significantly distinguish the mixed-genesis FLD from the AFLD (Volcano plot); these are the index of red blood cells destruction at a frequency of 5 ×105 Hz, which was higher with AFLD (p = 0.0007), and the capacity of cell membranes, the value of which prevailed in mixed-genesis FLD (p = 0.011). When distinguishing the mixed-genesis FLD from the AFLD, the combined model with the inclusion of three parameters of red blood cells, namely the index of red blood cells destruction at a frequency of 5 ×105 Hz, the capacity of erythrocyte membranes, and polarizability at a frequency of 106 Hz, has shown the highest levels of diagnostic accuracy, namely AUC = 0.751 (confidential interval: 0.611–0.908) with a sensitivity of 79.5 %, specificity of 74.7 %.</p></sec><sec><title>Conclusion</title><p>Conclusion. The electrical and viscoelastic parameters of erythrocytes studied using the diagnostic technique of dielectrophoresis should be considered as promising biomarkers for the diagnosis of diffuse liver disease. </p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>жировая болезнь печени</kwd><kwd>генез</kwd><kwd>диагностические модели</kwd><kwd>эритроциты</kwd><kwd>диэлектрофорез</kwd></kwd-group><kwd-group xml:lang="en"><kwd>fatty liver disease</kwd><kwd>genesis</kwd><kwd>diagnostic models</kwd><kwd>erythrocytes</kwd><kwd>red blood cells</kwd><kwd>dielectrophoresis</kwd></kwd-group><funding-group><funding-statement xml:lang="ru">Работа выполнена по Государственному заданию в рамках бюджетных тем «Изучение молекулярно-генетических и молекулярно-биологических механизмов развития распространенных терапевтических заболеваний в Сибири для совершенствования подходов к их ранней диагностике и профилактике», 2024–2028 гг. (FWNR-2024-0004), «Совершенствование методов диагностики, профилактики и лечения больных распространенными заболеваниями гепатобилиарной системы и желудочно-кишечного тракта в Сибири», 2023– 2025 гг. (FWNR-2023-0003).</funding-statement><funding-statement xml:lang="en">The work was carried out according to the State assignment within the framework of the budget themes “Study of molecular genetic and molecular biological mechanisms of the development of common therapeutic diseases in Siberia to improve approaches to their early diagnosis and prevention”, 2024–2028 (FWNR-2024-0004), “Improving methods of diagnosis, prevention and treatment of patients with common diseases of the hepatobiliary system and gastrointestinal tract in Siberia”, 2023–2025 (FWNR-2023-0003).</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Cotter T.G., Rinella M. Nonalcoholic fatty liver disease 2020: The state of the disease. Gastroenterology. 2020;158(7):1851–64. DOI: 10.1053/j.gastro.2020.01.052</mixed-citation><mixed-citation xml:lang="en">Cotter T.G., Rinella M. Nonalcoholic fatty liver disease 2020: The state of the disease. Gastroenterology. 2020;158(7):1851–64. DOI: 10.1053/j.gastro.2020.01.052</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Paik J.M., Golabi P., Biswas R., Alqahtani S., Venkatesan C., Younossi Z.M. Nonalcoholic fatty liver disease and alcoholic liver disease are major drivers of liver mortality in the United States. Hepatol Commun. 2020;4(6):890–903. DOI: 10.1002/hep4.1510</mixed-citation><mixed-citation xml:lang="en">Paik J.M., Golabi P., Biswas R., Alqahtani S., Venkatesan C., Younossi Z.M. Nonalcoholic fatty liver disease and alcoholic liver disease are major drivers of liver mortality in the United States. Hepatol Commun. 2020;4(6):890–903. DOI: 10.1002/hep4.1510</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Craciun A., Lackner C., Cortez-Pinto H. Nonalcoholic fatty liver disease versus alcohol-related liver disease: Is it really so different? Curr Pharm Des. 2020;26(10):1093–109. DOI: 10.2174/1381612826666200122152417</mixed-citation><mixed-citation xml:lang="en">Craciun A., Lackner C., Cortez-Pinto H. Nonalcoholic fatty liver disease versus alcohol-related liver disease: Is it really so different? Curr Pharm Des. 2020;26(10):1093–109. DOI: 10.2174/1381612826666200122152417</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016;64(6):1388–402. DOI: 10.1016/j.jhep.2015.11.004</mixed-citation><mixed-citation xml:lang="en">European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016;64(6):1388–402. DOI: 10.1016/j.jhep.2015.11.004</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Eslam M., Sanyal A.J., George J.; International Consensus Panel. MAFLD: A consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology. 2020;158(7):1999–2014.e1. DOI: 10.1053/j.gastro.2019.11.312</mixed-citation><mixed-citation xml:lang="en">Eslam M., Sanyal A.J., George J.; International Consensus Panel. MAFLD: A consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology. 2020;158(7):1999–2014.e1. DOI: 10.1053/j.gastro.2019.11.312</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Seitz H.K., Mueller S., Hellerbrand C., Liangpunsakul S. Effect of chronic alcohol consumption on the development and progression of non-alcoholic fatty liver disease (NAFLD). Hepatobiliary Surg Nutr. 2015;4(3):147–51. DOI: 10.3978/j.issn.2304-3881.2014.12.01</mixed-citation><mixed-citation xml:lang="en">Seitz H.K., Mueller S., Hellerbrand C., Liangpunsakul S. Effect of chronic alcohol consumption on the development and progression of non-alcoholic fatty liver disease (NAFLD). Hepatobiliary Surg Nutr. 2015;4(3):147–51. DOI: 10.3978/j.issn.2304-3881.2014.12.01</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Åberg F., Puukka P., Salomaa V., Männistö S., Lundqvist A., Valsta L., et al. Risks of light and moderate alcohol use in fatty liver disease: Follow-up of population cohorts. Hepatology. 2020;71(3):835–48. DOI: 10.1002/hep.30864</mixed-citation><mixed-citation xml:lang="en">Åberg F., Puukka P., Salomaa V., Männistö S., Lundqvist A., Valsta L., et al. Risks of light and moderate alcohol use in fatty liver disease: Follow-up of population cohorts. Hepatology. 2020;71(3):835–48. DOI: 10.1002/hep.30864</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Yi S.W., Choi J.S., Yi J.J., Lee Y.H., Han K.J. Risk factors for hepatocellular carcinoma by age, sex, and liver disorder status: A prospective cohort study in Korea. Cancer. 2018;124(13):2748–57. DOI: 10.1002/cncr.31406</mixed-citation><mixed-citation xml:lang="en">Yi S.W., Choi J.S., Yi J.J., Lee Y.H., Han K.J. Risk factors for hepatocellular carcinoma by age, sex, and liver disorder status: A prospective cohort study in Korea. Cancer. 2018;124(13):2748–57. DOI: 10.1002/cncr.31406</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Idalsoaga F., Kulkarni A.V., Mousa O.Y., Arrese M., Arab J.P. Non-alcoholic fatty liver disease and alcohol-related liver disease: Two intertwined entities. Front Med (Lausanne). 2020;7:448. DOI: 10.3389/fmed.2020.00448</mixed-citation><mixed-citation xml:lang="en">Idalsoaga F., Kulkarni A.V., Mousa O.Y., Arrese M., Arab J.P. Non-alcoholic fatty liver disease and alcohol-related liver disease: Two intertwined entities. Front Med (Lausanne). 2020;7:448. DOI: 10.3389/fmed.2020.00448</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Chen Z., Ma Y., Cai J., Sun M., Zeng L., Wu F. et al. Serum biomarkers for liver fibrosis. Clin Chim Acta. 2022;537:16–25. DOI: 10.1016/j.cca.2022.09.022</mixed-citation><mixed-citation xml:lang="en">Chen Z., Ma Y., Cai J., Sun M., Zeng L., Wu F. et al. Serum biomarkers for liver fibrosis. Clin Chim Acta. 2022;537:16–25. DOI: 10.1016/j.cca.2022.09.022</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Райхельсон К.Л., Маевская М.В., Жаркова М.С., Гречишникова В.Р., Оковитый С.В., Деева Т.А. и др. Жировая болезнь печени: новая номенклатура и ее адаптация в Российской Федерации. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2024;34(2):35–44. DOI: 10.22416/1382-4376-2024-961</mixed-citation><mixed-citation xml:lang="en">Raikhelson K.L., Maevskaya M.V., Zharkova M.S., Grechishnikova V.R., Okovityi S.V., Deeva T.A., et al. Steatotic liver disease: New nomenclature and its localization in the Russian Federation. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2024;34(2):35–44. (In Russ.)]. DOI: 10.22416/1382-4376-2024-961</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Кручинина М.В., Паруликова М.В., Курилович С.А., Громов А.А., Генералов В.М., Кручинин В.Н. и др. Возможности метода диэлектрофореза эритроцитов в дифференцировании жировой болезни печени алкогольного и неалкогольного генеза у мужчин. Атеросклероз. 2020;16(4):27–42. DOI: 10.15372/ATER20200404</mixed-citation><mixed-citation xml:lang="en">Kruchinina M.V., Parulikova M.V., Kurilovich S.A., Gromov A.A., Generalov V.M., Kruchinin V.N., et al. Possibilities of the method of dielectrophoresis of erythrocytes in distinction of patients with fatty liver disease of alcoholic and non-alcoholic genesis. Ateroscleroz. 2020;16(4):27–42. (In Russ.)]. DOI: 10.15372/ATER20200404</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Генералов В.М., Кручинина М.В., Дурыманов А.Г., Медведев А.А., Сафатов А.С., Сергеев А.Н. и др. Диэлектрофорез в диагностике инфекционных и неинфекционных заболеваний. Новосибирск: ЦЭРИС, 2011.</mixed-citation><mixed-citation xml:lang="en">Generalov V.M., Kruchinina M.V., Durymanov A.G., Medvedev A.A., Safatov A.S., Sergeev A.N., et al. Dielectrophoresis in the diagnosis of infectious and non-infectious diseases. Novosibirsk: CERIS Publ., 2011. (In Russ.)].</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Кручинина М.В., Паруликова М.В., Громов А.А., Генералов В.М., Генералов К.В., Кручинин В.Н. и др. Острое воздействие этанола на эритроциты in vitro: новый подход к дифференциальной диагностике жировой болезни печени. Экспериментальная и клиническая гастроэнтерология. 2019;172(12):122–34. DOI: 10.31146/1682-8658-ecg-172-12-122-134</mixed-citation><mixed-citation xml:lang="en">Kruchinina M.V., Parulikova M.V., Gromov A.A., Generalov V.M., Generalov K.V., Kruchinin V.N., et al. Acute effects of ethanol on erythrocytes in vitro: a new approach to differential diagnosis of fatty liver disease. Experimental and clinical gastroenterology. 2019;172(12):122–34. (In Russ.)]. DOI: 10.31146/1682-8658-ecg-172-12-122-134</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Кручинина М.В., Осипенко М.Ф., Паруликова М.В., Белковец А.В., Кручинина Э.В. Диагностические модели, включающие электрические, вязкоупругие параметры эритроцитов, для дифференцирования жировой болезни печени алкогольного и неалкогольного генеза. РМЖ. Медицинское обозрение. 2024;8(6): принято в печать.</mixed-citation><mixed-citation xml:lang="en">Kruchinina M.V., Osipenko M.F., Parulikova M.V., Belkovets A.V., Kruchinina E.V. Diagnostic models, including electrical, viscoelastic parameters of erythrocytes, for differentiating fatty liver disease of alcoholic and non-alcoholic origin. Russian Medical Inquiry. 2024;8(6): in press. (In Russ.)].</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Ивашкин В.Т., Маевская М.В., Жаркова М.С., Котовская Ю.В., Ткачева О.Н., Трошина Е.А. и др. Клинические рекомендации Российского общества по изучению печени, Российской гастроэнтерологической ассоциации, Российской ассоциации эндокринологов, Российской ассоциации геронтологов и гериатров и Национального общества профилактической кардиологии по диагностике и лечению неалкогольной жировой болезни печени. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2022;32(4):104–40. DOI: 10.22416/1382-4376-2022-32-4-104-140</mixed-citation><mixed-citation xml:lang="en">Ivashkin V.T., Maevskaya M.V., Zharkova M.S., Kotovskaya Yu.V., Tkacheva O.N., Troshina E.A., et al. Clinical practice guidelines of the Russian Scientific Liver Society, Russian Gastroenterological Association, Russian Association of Endocrinologists, Russian Association of Gerontologists and Geriatricians and National Society for Preventive Cardiology on diagnosis and treatment of non-alcoholic liver disease. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2022;32(4):104–40. (In Russ.)]. DOI: 10.22416/1382-4376-2022-32-4-104-140</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Khang A.R., Lee H.W., Yi D., Kang Y.H., Son S.M. The fatty liver index, a simple and useful predictor of metabolic syndrome: analysis of the Korea National Health and Nutrition Examination Survey 2010–2011. Diabetes Metab Syndr Obes. 2019;12:181–90. DOI: 10.2147/DMSO.S189544</mixed-citation><mixed-citation xml:lang="en">Khang A.R., Lee H.W., Yi D., Kang Y.H., Son S.M. The fatty liver index, a simple and useful predictor of metabolic syndrome: analysis of the Korea National Health and Nutrition Examination Survey 2010–2011. Diabetes Metab Syndr Obes. 2019;12:181–90. DOI: 10.2147/DMSO.S189544</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Рекомендации экспертов Всероссийского научного общества кардиологов по диагностике и лечению метаболического синдрома (2-й пересмотр). Практическая медицина. 2010;5(44):81–101.</mixed-citation><mixed-citation xml:lang="en">Recommendations of experts of the All-Russian Scientific Society of Cardiologists on the diagnosis and treatment of metabolic syndrome (2nd revision). Practical medicine. 2010;5(44):81–101. (In Russ.)].</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Kotronen A., Peltonen M., Hakkarainen A., Sevastianova K., Bergholm R., Johansson L.M., et al. Prediction of non-alcoholic fatty liver disease and liver fat using metabolic and genetic factors. Gastroenterology. 2009;137(3):865–72. DOI: 10.1053/j.gastro.2009.06.005</mixed-citation><mixed-citation xml:lang="en">Kotronen A., Peltonen M., Hakkarainen A., Sevastianova K., Bergholm R., Johansson L.M., et al. Prediction of non-alcoholic fatty liver disease and liver fat using metabolic and genetic factors. Gastroenterology. 2009;137(3):865–72. DOI: 10.1053/j.gastro.2009.06.005</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Shah A.G., Lydecker A., Murray K., Tetri B.N., Contos M.J., Sanyal A.J.; Nash Clinical Research Network. Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2009;7(10):1104–12. DOI: 10.1016/j.cgh.2009.05.033</mixed-citation><mixed-citation xml:lang="en">Shah A.G., Lydecker A., Murray K., Tetri B.N., Contos M.J., Sanyal A.J.; Nash Clinical Research Network. Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2009;7(10):1104–12. DOI: 10.1016/j.cgh.2009.05.033</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Breiman L. Random forests. Machine Learning. 2001;45:5–32. DOI: 10.1023/A:1010933404324</mixed-citation><mixed-citation xml:lang="en">Breiman L. Random forests. Machine Learning. 2001;45:5–32. DOI: 10.1023/A:1010933404324</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Uslusoy H.S., Nak S.G., Gülten M., Biyikli Z. Non-alcoholic steatohepatitis with normal aminotransferase values. World J Gastroenterol. 2009;15(15):1863–8. DOI: 10.3748/wjg.15.1863</mixed-citation><mixed-citation xml:lang="en">Uslusoy H.S., Nak S.G., Gülten M., Biyikli Z. Non-alcoholic steatohepatitis with normal aminotransferase values. World J Gastroenterol. 2009;15(15):1863–8. DOI: 10.3748/wjg.15.1863</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Burt A.D., Ferrell L.D., Hübscher S.G. MacSween's pathology of the liver, 8th Edition. Elsevier; 2024.</mixed-citation><mixed-citation xml:lang="en">Burt A.D., Ferrell L.D., Hübscher S.G. MacSween's pathology of the liver, 8th Edition. Elsevier; 2024.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Zhang X., Wong G.L., Wong V.W. Application of transient elastography in nonalcoholic fatty liver disease. Clin Mol Hepatol. 2020;26(2):128–41. DOI: 10.3350/cmh.2019.0001n</mixed-citation><mixed-citation xml:lang="en">Zhang X., Wong G.L., Wong V.W. Application of  transient elastography in nonalcoholic fatty liver disease. Clin Mol Hepatol. 2020;26(2):128–41. DOI: 10.3350/cmh.2019.0001n</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Osna N.A., Tikhanovich I., Ortega-Ribera M., Mueller S., Zheng C., Mueller J., et al. Alcohol-associated liver disease outcomes: Critical mechanisms of liver injury progression. Biomolecules. 2024;14(4):404. DOI: 10.3390/biom14040404</mixed-citation><mixed-citation xml:lang="en">Osna N.A., Tikhanovich I., Ortega-Ribera M., Mueller S., Zheng C., Mueller J., et al. Alcohol-associated liver disease outcomes: Critical mechanisms of liver injury progression. Biomolecules. 2024;14(4):404. DOI: 10.3390/biom14040404</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Mueller S. Pathophysiology of alcoholic hepatitis: Emerging role of enhanced red blood cell turnover. In: Mueller S., Heilig M. (eds) Alcohol and alcohol-related diseases. Springer, Cham; 2023:1211–23. DOI: 10.1007/978-3-031-32483-3_64</mixed-citation><mixed-citation xml:lang="en">Mueller S. Pathophysiology of alcoholic hepatitis: Emerging role of enhanced red blood cell turnover. In: Mueller S., Heilig M. (eds) Alcohol and alcohol-related diseases. Springer, Cham; 2023:1211–23. DOI: 10.1007/978-3-031-32483-3_64</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Wang Y., Yang P., Yan Z., Liu Z., Ma Q., Zhang Z., et al. The relationship between erythrocytes and diabetes mellitus. J Diabetes Res. 2021;2021:6656062. DOI: 10.1155/2021/6656062</mixed-citation><mixed-citation xml:lang="en">Wang Y., Yang P., Yan Z., Liu Z., Ma Q., Zhang Z., et al. The relationship between erythrocytes and diabetes mellitus. J Diabetes Res. 2021;2021:6656062. DOI: 10.1155/2021/6656062</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Kruchinina M.V., Gromov A.A., Generalov V.M., Kruchinin V.N. Possible differential diagnosis of the degrees of rheological disturbances in patients with type 2 diabetes mellitus by dielectrophoresis of erythrocytes. J Pers Med. 2020;10(3):60. DOI: 10.3390/jpm10030060</mixed-citation><mixed-citation xml:lang="en">Kruchinina M.V., Gromov A.A., Generalov V.M., Kruchinin V.N. Possible differential diagnosis of the degrees of rheological disturbances in patients with type 2 diabetes mellitus by dielectrophoresis of erythrocytes. J Pers Med. 2020;10(3):60. DOI: 10.3390/jpm10030060</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Mueller S. Evidence for red blood cell-derived aspartate aminotransferase in heavy drinkers. In: Mueller S., Heilig M. (eds) Alcohol and alcohol-related diseases. Springer, Cham; 2023:785–93. DOI: 10.1007/978-3-031-32483-3_41</mixed-citation><mixed-citation xml:lang="en">Mueller S. Evidence for red blood cell-derived aspartate aminotransferase in heavy drinkers. In: Mueller S., Heilig M. (eds) Alcohol and alcohol-related diseases. Springer, Cham; 2023:785–93. DOI: 10.1007/978-3-031-32483-3_41</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Kruchinina M.V., Kurilovich S.А., Gromov А.А., Generalov V.М., Kruchinin V.N. Peculiarities of erythrocytic parameters in patients with nonalcoholic steatohepatitis. Journal of Analytical Sciences, Methods and Instrumentation. 2016;6(1):6–14. DOI: 10.4236/jasmi.2016.61002</mixed-citation><mixed-citation xml:lang="en">Kruchinina M.V., Kurilovich S.А., Gromov А.А., Generalov V.М., Kruchinin V.N. Peculiarities of erythrocytic parameters in patients with nonalcoholic steatohepatitis. Journal of Analytical Sciences, Methods and Instrumentation. 2016;6(1):6–14. DOI: 10.4236/jasmi.2016.61002</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Dimeski G., Mollee P., Carter A. Increased lipid concentration is associated with increased hemolysis. Clin Chem. 2005;51(12):2425. DOI: 10.1373/clinchem.2005.058644</mixed-citation><mixed-citation xml:lang="en">Dimeski G., Mollee P., Carter A. Increased lipid concentration is associated with increased hemolysis. Clin Chem. 2005;51(12):2425. DOI: 10.1373/clinchem.2005.058644</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Gils C., Hansen D.L., Nybo M., Frederiksen H. Elevated Hemolysis Index is associated with higher risk of cardiovascular diseases. Clin Chem Lab Med. 2023;61(8):1497–505. DOI: 10.1515/cclm-2023-0114</mixed-citation><mixed-citation xml:lang="en">Gils C., Hansen D.L., Nybo M., Frederiksen H. Elevated Hemolysis Index is associated with higher risk of cardiovascular diseases. Clin Chem Lab Med. 2023;61(8):1497–505. DOI: 10.1515/cclm-2023-0114</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Wang Y., Ming J., Guo Z., Zhang W., Li X., Zhou S., et al. Association of serum uric acid with anemia in U.S. adults: A cross-sectional study using secondary data. BMC Cardiovasc Disord. 2023;23(1):291. DOI: 10.1186/s12872-023-03291-y</mixed-citation><mixed-citation xml:lang="en">Wang Y., Ming J., Guo Z., Zhang W., Li X., Zhou S., et al. Association of serum uric acid with anemia in U.S. adults: A cross-sectional study using secondary data. BMC Cardiovasc Disord. 2023;23(1):291. DOI: 10.1186/s12872-023-03291-y</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Bertola A., Mathews S., Ki S.H., Wang H., Gao B. Mouse model of chronic and binge ethanol feeding (the NIAAA model). Nat Protoc. 2013;8(3):627–37. DOI: 10.1038/nprot.2013.032</mixed-citation><mixed-citation xml:lang="en">Bertola A., Mathews S., Ki S.H., Wang H., Gao B. Mouse model of chronic and binge ethanol feeding (the NIAAA model). Nat Protoc. 2013;8(3):627–37. DOI: 10.1038/nprot.2013.032</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Mueller S., Chen C., Mueller J., Wang S. Novel Insights into Alcoholic Liver Disease: Iron Overload, Iron Sensing and Hemolysis. J Transl Int Med. 2022;10(2):92-124. DOI: 10.2478/jtim-2021-0056</mixed-citation><mixed-citation xml:lang="en">Mueller S., Chen C., Mueller J., Wang S. Novel Insights into Alcoholic Liver Disease: Iron Overload, Iron Sensing and Hemolysis. J Transl Int Med. 2022;10(2):92-124. DOI: 10.2478/jtim-2021-0056</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">Mueller S., Mueller J. Alcohol and mortality: First preliminary lessons from a prospective 15 year follow-up study In: Mueller S., Heilig M. (eds) Alcohol and alcohol-related diseases. Springer, Cham; 2023:81–102. DOI: 10.1007/978-3-031-32483-3_7</mixed-citation><mixed-citation xml:lang="en">Mueller S., Mueller J. Alcohol and mortality: First preliminary lessons from a prospective 15 year follow-up study In: Mueller S., Heilig M. (eds) Alcohol and alcohol-related diseases. Springer, Cham; 2023:81–102. DOI: 10.1007/978-3-031-32483-3_7</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">Chi L.M., Wu W.G. Mechanism of hemolysis of red blood cell mediated by ethanol. Biochim Biophys Acta. 1991;1062(1):46–50. DOI: 10.1016/0005-2736(91)90333-4</mixed-citation><mixed-citation xml:lang="en">Chi L.M., Wu W.G. Mechanism of hemolysis of red blood cell mediated by ethanol. Biochim Biophys Acta. 1991;1062(1):46–50. DOI: 10.1016/0005-2736(91)90333-4</mixed-citation></citation-alternatives></ref><ref id="cit38"><label>38</label><citation-alternatives><mixed-citation xml:lang="ru">Bartel M., Hofmann V., Wang S., Mueller J., Sundermann T.R., Mueller S. Confounders of serum phosphatidylethanol: Role of red blood cell turnover and cirrhosis. Hepat Med. 2023;15:195–208. DOI: 10.2147/HMER.S420732</mixed-citation><mixed-citation xml:lang="en">Bartel M., Hofmann V., Wang S., Mueller J., Sundermann T.R., Mueller S. Confounders of serum phosphatidylethanol: Role of red blood cell turnover and cirrhosis. Hepat Med. 2023;15:195–208. DOI: 10.2147/HMER.S420732</mixed-citation></citation-alternatives></ref><ref id="cit39"><label>39</label><citation-alternatives><mixed-citation xml:lang="ru">Immenschuh S., Baumgart-Vogt E., Mueller S. Heme oxygenase-1 and iron in liver inflammation: A complex alliance. Curr Drug Targets. 2010;11(12):1541–50. DOI: 10.2174/1389450111009011541</mixed-citation><mixed-citation xml:lang="en">Immenschuh S., Baumgart-Vogt E., Mueller S. Heme oxygenase-1 and iron in liver inflammation: A complex alliance. Curr Drug Targets. 2010;11(12):1541–50. DOI: 10.2174/1389450111009011541</mixed-citation></citation-alternatives></ref><ref id="cit40"><label>40</label><citation-alternatives><mixed-citation xml:lang="ru">Sebastián J.L., Muñoz S., Sancho M., Martínez G., Kaler K.V. Polarizability of red blood cells with an anisotropic membrane. Phys Rev E. 2010;81(2):022901. DOI: 10.1103/PhysRevE.81.022901</mixed-citation><mixed-citation xml:lang="en">Sebastián J.L., Muñoz S., Sancho M., Martínez G., Kaler K.V. Polarizability of red blood cells with an anisotropic membrane. Phys Rev E. 2010;81(2):022901. DOI: 10.1103/PhysRevE.81.022901</mixed-citation></citation-alternatives></ref><ref id="cit41"><label>41</label><citation-alternatives><mixed-citation xml:lang="ru">Generalov K., Generalov V., Safatov A., Durymanov A., Buryak G., Kruchinina M., et al. Nonlinear polarizability of erythrocytes in non-uniform alternating electric field. Open Journal of Biophysics. 2014;4:97–103. DOI: 10.4236/ojbiphy.2014.43011</mixed-citation><mixed-citation xml:lang="en">Generalov K., Generalov V., Safatov A., Durymanov A., Buryak G., Kruchinina M., et al. Nonlinear polarizability of erythrocytes in non-uniform alternating electric field. Open Journal of Biophysics. 2014;4:97–103. DOI: 10.4236/ojbiphy.2014.43011</mixed-citation></citation-alternatives></ref><ref id="cit42"><label>42</label><citation-alternatives><mixed-citation xml:lang="ru">Jovtchev S., Djenev I., Stoeff S., Stoylov S. Role of electrical and mechanical properties of red blood cells for their aggregation. Colloids and Surfaces A: Physicochemical and Engineering Aspects. 2000;164(2–3):95–104. DOI: 10.1016/S0927-7757(99)00345-3</mixed-citation><mixed-citation xml:lang="en">Jovtchev S., Djenev I., Stoeff S., Stoylov S. Role of electrical and mechanical properties of red blood cells for their aggregation. Colloids and Surfaces A: Physicochemical and Engineering Aspects. 2000;164(2–3):95–104. DOI: 10.1016/S0927-7757(99)00345-3</mixed-citation></citation-alternatives></ref><ref id="cit43"><label>43</label><citation-alternatives><mixed-citation xml:lang="ru">Ebrahimi S., Bagchi P. A computational study of red blood cell deformability effect on hemodynamic alteration in capillary vessel networks. Sci Rep. 2022;12(1):4304. DOI: 10.1038/s41598-022-08357-z</mixed-citation><mixed-citation xml:lang="en">Ebrahimi S., Bagchi P. A computational study of red blood cell deformability effect on hemodynamic alteration in capillary vessel networks. Sci Rep. 2022;12(1):4304. DOI: 10.1038/s41598-022-08357-z</mixed-citation></citation-alternatives></ref><ref id="cit44"><label>44</label><citation-alternatives><mixed-citation xml:lang="ru">Chen W., Shao S., Cai H., Han J., Guo T., Fu Y., et al. Comparison of erythrocyte membrane lipid profiles between NAFLD patients with or without hyperlipidemia. Int J Endocrinol. 2020;2020:9501826. DOI: 10.1155/2020/9501826</mixed-citation><mixed-citation xml:lang="en">Chen W., Shao S., Cai H., Han J., Guo T., Fu Y., et al. Comparison of erythrocyte membrane lipid profiles between NAFLD patients with or without hyperlipidemia. Int J Endocrinol. 2020;2020:9501826. DOI: 10.1155/2020/9501826</mixed-citation></citation-alternatives></ref><ref id="cit45"><label>45</label><citation-alternatives><mixed-citation xml:lang="ru">Rabai M., Detterich J.A., Wenby R.B., Toth K., Meiselman H.J. Effects of ethanol on red blood cell rheological behavior. Clin Hemorheol Microcirc. 2014;56(2):87–99. DOI: 10.3233/CH-2012-1632</mixed-citation><mixed-citation xml:lang="en">Rabai M., Detterich J.A., Wenby R.B., Toth K., Meiselman H.J. Effects of ethanol on red blood cell rheological behavior. Clin Hemorheol Microcirc. 2014;56(2):87–99. DOI: 10.3233/CH-2012-1632</mixed-citation></citation-alternatives></ref><ref id="cit46"><label>46</label><citation-alternatives><mixed-citation xml:lang="ru">Palmieri V.O., Cicco G., Minerva F., Portincasa P., Grattagliano I., Memeo V., et al. Red blood cells (RBC) deformability and aggregability: Alterations in alcoholism. Adv Exp Med Biol. 2006;578:125–31. DOI: 10.1007/0387-29540-2_20</mixed-citation><mixed-citation xml:lang="en">Palmieri V.O., Cicco G., Minerva F., Portincasa P., Grattagliano I., Memeo V., et al. Red blood cells (RBC) deformability and aggregability: Alterations in alcoholism. Adv Exp Med Biol. 2006;578:125–31. DOI: 10.1007/0387-29540-2_20</mixed-citation></citation-alternatives></ref><ref id="cit47"><label>47</label><citation-alternatives><mixed-citation xml:lang="ru">Liu L., Huang S., Xu X., Han J. Study of individual erythrocyte deformability susceptibility to INFeD and ethanol using a microfluidic chip. Sci Rep. 2016;6:22929. DOI: 10.1038/srep22929</mixed-citation><mixed-citation xml:lang="en">Liu L., Huang S., Xu X., Han J. Study of individual erythrocyte deformability susceptibility to INFeD and ethanol using a microfluidic chip. Sci Rep. 2016;6:22929. DOI: 10.1038/srep22929</mixed-citation></citation-alternatives></ref><ref id="cit48"><label>48</label><citation-alternatives><mixed-citation xml:lang="ru">Brun J.F., Varlet-Marie E., Myzia J., Raynaud de Mauverger E., Pretorius E. Metabolic influences modulating erythrocyte deformability and eryptosis. Metabolites. 2021;12(1):4. DOI: 10.3390/metabo12010004</mixed-citation><mixed-citation xml:lang="en">Brun J.F., Varlet-Marie E., Myzia J., Raynaud de Mauverger E., Pretorius E. Metabolic influences modulating erythrocyte deformability and eryptosis. Metabolites. 2021;12(1):4. DOI: 10.3390/metabo12010004</mixed-citation></citation-alternatives></ref><ref id="cit49"><label>49</label><citation-alternatives><mixed-citation xml:lang="ru">Carquin M., D'Auria L., Pollet H., Bongarzone E.R., Tyteca D. Recent progress on lipid lateral heterogeneity in plasma membranes: From rafts to submicrometric domains. Prog Lipid Res. 2016;62:1–24. DOI: 10.1016/j.plipres.2015.12.004</mixed-citation><mixed-citation xml:lang="en">Carquin M., D'Auria L., Pollet H., Bongarzone E.R., Tyteca D. Recent progress on lipid lateral heterogeneity in plasma membranes: From rafts to submicrometric domains. Prog Lipid Res. 2016;62:1–24. DOI: 10.1016/j.plipres.2015.12.004</mixed-citation></citation-alternatives></ref><ref id="cit50"><label>50</label><citation-alternatives><mixed-citation xml:lang="ru">Bulle S., Reddy V.D., Padmavathi P., Maturu P., Puvvada P.K., Nallanchakravarthula V. Association between alcohol-induced erythrocyte membrane alterations and hemolysis in chronic alcoholics. J Clin Biochem Nutr. 2017;60(1):63–9. DOI: 10.3164/jcbn.16-16</mixed-citation><mixed-citation xml:lang="en">Bulle S., Reddy V.D., Padmavathi P., Maturu P., Puvvada P.K., Nallanchakravarthula V. Association between alcohol-induced erythrocyte membrane alterations and hemolysis in chronic alcoholics. J Clin Biochem Nutr. 2017;60(1):63–9. DOI: 10.3164/jcbn.16-16</mixed-citation></citation-alternatives></ref><ref id="cit51"><label>51</label><citation-alternatives><mixed-citation xml:lang="ru">Кручинина М.В., Осипенко М.Ф., Паруликова М.В., Кручинина Э.В. Жирные кислоты мембран эритроцитов в дифференцировании пациентов с жировой болезнью печени алкогольного, неалкогольного и смешанного генеза. Эффективная фармакотерапия. 2023;19(43):28–41. DOI: 10.33978/23073586-2023-19-43-28-41</mixed-citation><mixed-citation xml:lang="en">Kruchinina M.V., Osipenko M.F., Parulikova M.V., Kruchinina E.V. Fatty acids of erythrocyte membranes in differentiating patients with fatty liver disease of alcoholic, non-alcoholic and mixed origin. Effective pharmacotherapy. 2023;19(43):28–41. (In Russ.)]. DOI: 10.33978/23073586-2023-19-43-28-41</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
